Home › Trials › NCT06851858

Evaluating AZD6234 for overweight or obese adults with type 2 diabetes on GLP-1 therapy

A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

Phase 2 Interventional AstraZeneca · NCT06851858

This study is testing if a new medication called AZD6234 can help overweight or obese adults with type 2 diabetes who are already using GLP-1 therapy manage their diabetes and lose weight better.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment64 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorAstraZeneca Industry-sponsored
Locations16 sites (Birmingham, Alabama and 15 other locations)
Trial IDNCT06851858 on ClinicalTrials.gov

What this trial studies

This Phase II study is a randomized, double-blind, placebo-controlled trial assessing the efficacy, safety, and tolerability of AZD6234 in adults aged 18-75 who are overweight or obese and have type 2 diabetes while on a stable dose of GLP-1 receptor agonist therapy. Participants will receive weekly subcutaneous injections of either AZD6234 or a placebo for a specified treatment period. The study aims to determine if AZD6234 can provide additional benefits in managing diabetes and weight in this population. A total of 64 participants will be enrolled across multiple sites in the USA.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-75 with type 2 diabetes, a BMI of 27 kg/m² or higher, and currently stable on GLP-1 receptor agonist therapy.

Not a fit: Patients who have undergone recent weight loss treatments or have significant renal or hepatobiliary diseases may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could improve diabetes management and weight control for patients already on GLP-1 receptor agonists.

How similar studies have performed: Other studies have shown promise with similar approaches, but this specific intervention is novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Be 18 to 75 years old at the time of signing the informed consent.
2. Diagnosed with type 2 diabetes ≥ 180 days before screening.
3. HbA1c value at screening of ≥ 7.0% (53 mmol/mol) and ≤ 10% (86 mmol/mol).
4. On a stable maintenance dose of an injectable GLP-1 RA.
5. At Screening, have a BMI ≥ 27 kg/m2

Exclusion Criteria:

1. Has received treatment with prescription or non-prescription medication for weight loss within the last 3 months prior to screening (other than a GLP-1 RA).
2. Self-reported weight change of \> 5 % in the 3 months prior to screening.
3. Diabetes mellitus that is not clearly type 2 diabetes.
4. Use of insulin therapy for T2DM
5. Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier)
6. Significant hepatobiliary disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis)

8. Impaired renal function defined as eGFR ≤ 45 mL/minute/1.73m2 at screening

Where this trial is running

Birmingham, Alabama and 15 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions EndocrinologyDiabetes, Type IIObesity
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.